Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.43 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23343773 | 0.84 | CA1 (0.39) | LPAR1HDAC4HDAC8KCNK3KCNK9 | |
| SCHEMBL3698795 | 0.84 | ALDH1A1 (0.42) | CA1CA2CA12CA4CA7 | |
| SCHEMBL19997514 | 0.84 | CA1 (0.39) | LPAR1HDAC4HDAC8KCNK3KCNK9 | |
| SCHEMBL16961396 | 0.84 | CA1 (0.39) | LPAR1HDAC4HDAC8KCNK3KCNK9 | |
| SCHEMBL16794998 | 0.84 | LMNA (0.41) | LPAR1KCNK3KCNK9CA1CA2 | |
| SCHEMBL22827469 | 0.83 | KRAS (0.44) | HDAC4HDAC8CA1CA2CA12 | |
| Hydrochloric Acid SCHEMBL22836784 | 0.82 | ALDH1A1 (0.43) | CA1CA2CA12CA4CA7 | |
| Hydrochloric Acid SCHEMBL22836785 | 0.82 | ALDH1A1 (0.43) | CA1CA2CA12CA4CA7 | |
| SCHEMBL26550976 | 0.82 | GABRA1 (0.40) | LPAR1KCNK3KCNK9CA1CA2 | |
| SCHEMBL13450392 | 0.82 | GABRA1 (0.40) | KCNK3KCNK9CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-11793771-B2 | Immunomodulator compounds | CHEMOCENTRYX, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| WO-2023196975-A1 | COMPOUNDS THAT INTERACT WITH RAS SUPERFAMILY PROTEINS FOR TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, LLC (US) | 2023-10-12 | — | — | WO | disclosed |
| EP-3686197-B1 | 2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-06-21 | — | — | EP | disclosed |
| WO-2023086539-A2 | BCAT2 INHIBITORS | AGIOS PHARMACEUTICALS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-11649229-B2 | Amide compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11634425-B2 | Pharmaceutical compounds | PFIZER INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| WO-2022136914-A1 | TYK2 INHIBITORS AND USES THEREOF | SUDO BIOSCIENCES LIMITED (GB) | 2022-06-30 | — | — | WO | disclosed |
| US-20070299087-A1 | New Compounds 319 | ASTRAZENECA AB (SE) | 2007-12-27 | — | — | US | disclosed |
| US-20070299087-A1 | New Compounds 319 | ASTRAZENECA AB (SE) | 2007-12-27 | — | — | US | disclosed |
| WO-2007145568-A1 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007145569-A1 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2007-12-21 | — | — | WO | disclosed |
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION | 2007-06-28 | — | — | US | disclosed |
| EP-1757591-A1 | CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-7179815-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-20040152736-A1 | Thrombin receptor antagonists | TOPROL ACQUISITION LLC | 2004-08-05 | — | — | US | disclosed |
| US-20040152736-A1 | Thrombin receptor antagonists | TOPROL ACQUISITION LLC | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299087-A1 | New Compounds 319 | PSEN2, PSEN1, MAPT | LPAR1 1692/4885HDAC4 450/4885HDAC8 1093/4885 |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | LPAR1 2274/4885HDAC4 2221/4885HDAC8 2989/4885 |
| US-11649229-B2 | Amide compounds for treatment of immune and inflammatory disorders | CFD, TFPI, CFH | LPAR1 1706/4885HDAC4 528/4885HDAC8 419/4885 |
| US-20040152736-A1 | Thrombin receptor antagonists | CNR1, TBXA2R, CNR2 | LPAR1 159/4885HDAC4 3659/4885HDAC8 3217/4885 |
| US-11793771-B2 | Immunomodulator compounds | IL2, IL2RA, C3AR1 | LPAR1 521/4885HDAC4 2532/4885HDAC8 2445/4885 |
| US-11634425-B2 | Pharmaceutical compounds | GABRA6, CHRNA6, CNR1 | LPAR1 2128/4885HDAC4 1224/4885HDAC8 172/4885 |
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | LPAR1 281/4885HDAC4 1752/4885HDAC8 1388/4885 |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | JAK1, JAK3, JAK2 | LPAR1 2437/4885HDAC4 1988/4885HDAC8 1794/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | LPAR1 2279/4885HDAC4 3902/4885HDAC8 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.